New cancer drug could give hope to non-responsive patients

A new dual action drug developed as part of a collaboration between biopharmaceutical oncology firm Almac Discovery and The Royal College of Surgeons in Ireland (RCSI) could be used to treat cancer patients in whom all other treatment avenues have failed. In development for 10 years, ALM201 entered the clinical trial stage in 2015 and the research team at RCSI have now established the maximum tolerated dose, as lead researcher Proffesor Tracy Robson explained: “We started off with a low dose of the drug and then incrementally increased it so we can establish the best dose to use without toxicity. We have seen no toxicity at all, which is really good news.